SOURCE: BioTech Medics, Inc.

June 14, 2007 09:44 ET

BioTech Medics, Inc. CEO Featured in Interview on Market News First: MN1.COM

DALLAS, TX--(Marketwire - June 14, 2007) - BioTech Medics, Inc. (PINKSHEETS: BTME) announces that Keith Houser, Chairman and CEO, will be featured at 10:15AM CDT today in an interview on Market News First located on Market News First's Internet website at www.MN1.com. Discussions include some of the Company history as well as what the Company's projections are for the long- term investor.

BioTech Medics is a high-powered therapeutic medical laser manufacturer and distributor of Class IIIB-FDA cleared non-hazardous lasers which are a revolutionary treatment for the reduction and/or elimination of acute and chronic muscular, skeletal and/or arthritic pain. BioTech' exclusive and proprietary L3aser Protocol Therapy is effective, economical, non-surgical, drug-free pain management which offers results for millions of people who suffer from pain everyday as a top priority in today's fast paced life and rapidly changing healthcare environment.

Conditions such as carpal tunnel, back aches, herniated disk pain, neck pain, knee & hip pain, TMJ pain, joint pain, nerve pain, sports injuries, accidents, work related injuries or just ailments from aging can be treated easily and non-surgically in one of BioTech's Pain Management & Wellness Centers.

BTME is alternative medicine for the twenty-first century. BioTech is the patent holder of SHBAN™ Hand Sanitizer which is a non-toxic antimicrobial clinically proven to kill the Avian Bird Flu Virus together with most common germs, and bacteria. SHBAN is superior to other hand sanitizers. SHBAN does not contain any alcohol. SHBAN is non-toxic (when used as directed) and leaves an invisible odorless protective film on your hands for long-lasting protection.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has made no evaluation of SHBAN. SHBAN is not made to diagnose, prevent, cure or treat any disease. No compensation was paid to Market News First for this interview.

Contact Information

  • Contact:

    Investor Relations
    1-800-200-2458